MOLBIO · Molbio Diagnostics Limited · Documents

1,494.80 INR +100.20 (+7.18%) At close · Nov 13

Rebalance outlook locked

Volume · Nov 13 174.18K Avg daily vol (3M) 381.02K

Summary

Financials

Earnings & Events

Webcasts Investor Relations

Ownership

Held by Funds

Filings

Documents

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 5, 2026

2026

Nov 5

Earnings call

Revenue dips as FY27 growth guidance remains intact

Molbio Diagnostics reported H1 FY27 INR667 crores in operating revenue versus INR680 crores, with INR153 crores EBITDA at a 23% margin and INR60 crores PAT. Management retained FY27 guidance for 25% top-line growth and a 24% to 25% EBITDA margin.

8 source passages

Thank you. Good evening, everyone, and thank you for joining us on the Q2 and H1 FY27 results conference call of Molbio Diagnostics Limited. On a consolidated basis, we delivered revenue from operations of INR667 crores in H1 FY27 versus INR680 crores in H1 of last year. Our EBITDA for H1 FY27 is INR153 crores, which represents a margin of 23% of total revenue. Our PAT for H1 FY27 is INR60 crores. So from a management guidance perspective, we are on track for that. So from a management guidance perspective, we see that we are on track for that. And with that, thank you all for attending our Q2 earnings call for fiscal 2027. And just to reiterate, as Mr. Sriram had mentioned, we believe that in terms of our model and in terms of our growth and in terms of our guidance, we continue to remain focused in terms of targeting the 25% top line growth for the current fiscal with about a 24% to 25% EBITDA margin. Open the document at this passage

Sep 8

Earnings call

Q1 2027 earnings call AI summary on its way

Showing 1–2 of 2 documents